Trial intelligence / Profile preview

Inhaled NO Therapy for Prevention of Nosocomial Pneumonia After Cardiac Surgery

NCT06162455Completed

Sponsor
Tomsk National Research Medical Centre of the Russian Academy of Sciences
Start
Nov 2023
Primary completion
Jan 2024
Modality
DNA Intercalators/Alkylators, Inhalation Devices
Countries
1
01

Overview

Randomised, double-blind trial of nitric oxide in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoint: Incidence of nosocomial pneumonia. Started Nov 2023; status: completed.

02

Drugs

nitric oxide
03

Conditions

hospital-acquired pneumonia (HAP)

Beyond the preview

Go deeper on NCT06162455.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06162455.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call